Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMTS4520 for Chronic Diarrhoea
NCT06839586Phase 2Active, not recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Feb 2025
- Primary completion
- Jan 2030
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic diarrhea comparing CMTS4520 Group with Placebo Group (2 arms). Primary endpoint: The clinical response rate after treatment at 8 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
CMTS4520
03
Conditions
Chronic diarrhea
Beyond the preview
Go deeper on NCT06839586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839586.